GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland Sells 23,108 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 23,108 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $70.48, for a total value of $1,628,651.84. Following the completion of the transaction, the chief executive officer now directly owns 82,318 shares of the company’s stock, valued at $5,801,772.64. The trade was a 21.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Katherine Stueland also recently made the following trade(s):

• On Monday, November 18th, Katherine Stueland sold 22,307 shares of GeneDx stock. The stock was sold at an average price of $70.34, for a total value of $1,569,074.38.
• On Tuesday, October 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The stock was sold at an average price of $66.60, for a total value of $143,456.40.
• On Monday, September 9th, Katherine Stueland sold 3,639 shares of GeneDx stock. The shares were sold at an average price of $33.33, for a total transaction of $121,287.87.

GeneDx Stock Performance

Shares of NASDAQ WGS opened at $69.38 on Thursday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. GeneDx Holdings Corp. has a 1 year low of $1.29 and a 1 year high of $89.11. The firm’s 50 day moving average price is $58.11 and its 200 day moving average price is $38.91.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.25. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The firm had revenue of $76.90 million for the quarter, compared to analyst estimates of $64.98 million. During the same period last year, the company earned ($0.82) EPS. The firm’s quarterly revenue was up 44.3% on a year-over-year basis. Equities analysts forecast that GeneDx Holdings Corp. will post -0.24 EPS for the current fiscal year.

Institutional Trading of GeneDx

Several institutional investors have recently made changes to their positions in WGS. Acadian Asset Management LLC purchased a new position in GeneDx in the second quarter valued at approximately $34,000. nVerses Capital LLC acquired a new position in shares of GeneDx during the 2nd quarter valued at $50,000. CWM LLC purchased a new stake in GeneDx during the 3rd quarter worth $89,000. SG Americas Securities LLC acquired a new stake in GeneDx in the 3rd quarter valued at $198,000. Finally, Point72 DIFC Ltd acquired a new stake in GeneDx in the 3rd quarter valued at $220,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

WGS has been the subject of a number of research reports. TD Cowen lifted their target price on shares of GeneDx from $46.00 to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. BTIG Research upped their target price on GeneDx from $35.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, July 31st. Wells Fargo & Company increased their target price on GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, October 30th. Craig Hallum boosted their price target on GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Finally, The Goldman Sachs Group increased their price objective on GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, GeneDx has a consensus rating of “Moderate Buy” and an average target price of $59.33.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.